<DOC>
	<DOCNO>NCT03057795</DOCNO>
	<brief_summary>This phase II trial study well nivolumab brentuximab vedotin work stem cell transplant treat patient high-risk classical Hodgkin lymphoma come back respond treatment . Monoclonal antibody , nivolumab brentuximab vedotin , may interfere ability cancer cell grow spread .</brief_summary>
	<brief_title>Nivolumab Brentuximab Vedotin After Stem Cell Transplant Treating Patients With Relapsed Refractory High-Risk Classical Hodgkin Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I. Assess efficacy nivolumab plus brentuximab vedotin consolidation autologous stem cell transplantation ( ASCT ) participant relapsed/refractory Hodgkin lymphoma ( HL ) , assess 18-month progression-free survival ( PFS ) . SECONDARY OBJECTIVES : I . Estimate overall survival ( OS ) , cumulative incidence relapse/progression , cumulative incidence non-relapse mortality ( TRM ) participant relapsed/ refractory HL receive nivolumab plus brentuximab vedotin consolidation ASCT . II . Estimate overall response rate nivolumab plus brentuximab vedotin therapy participant measurable disease ASCT . III . Establish safety tolerability nivolumab plus brentuximab vedotin use consolidation ASCT participant relapsed/ refractory HL . TERTIARY OBJECTIVES : I . Evaluate Lymphoma Response Immunomodulatory therapy Criteria ( LYRIC ) definition indeterminate response guide management patient regard treatment past progressive disease . II . Explore impact nivolumab plus brentuximab vedotin therapy immune reconstitution ASCT . III . Explore prognostic impact temporal dynamic minimal residual disease ( MRD ) peripheral blood assess next-generation sequencing-based ClonoSEQ platform . IV . Explore prognostic impact 9p24.1 abnormality tumor tissue assess fluorescence situ hybridization ( FISH ) outcomes ASCT nivolumab plus brentuximab vedotin post-ASCT consolidation therapy . V. Explore relationship immune cell Hodgkin Reed/Sternberg ( HRS ) tumor sample 6-color quantitative spatial image analysis use Vectra system , correlate outcome ASCT nivolumab plus brentuximab vedotin post-ASCT consolidation therapy . VI . Explore whether genetic alteration ( e.g . gene expression profile genetic mutation ) HL tumor sample associate outcome ASCT nivolumab plus brentuximab vedotin post-ASCT consolidation therapy . OUTLINE : Beginning 30-60 day post-ASCT , patient receive brentuximab vedotin intravenously ( IV ) 30 minute nivolumab IV 60 minute day 1 . Treatment repeat every 21 day 8 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow 30 100 day , 5 , 7 , 12 , 18 month , biannually thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>Documented informed consent Agreement allow use archival tissue preASCT tumor biopsy If unavailable , exception may grant study principal investigator ( PI ) approval Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 Histologically confirm diagnosis classical Hodgkin lymphoma ( exclude nodular lymphocyte predominant Hodgkin lymphoma ) accord World Health Organization ( WHO ) classification , hematopathology review participate institution Have highrisk relapse refractory Hodgkin lymphoma ( HL ) , define : Primary refractory disease frontline therapy Relapse within 1 year complete frontline therapy Extranodal involvement time preASCT relapse B symptom preASCT relapse More one type preASCT salvage therapy require Planning receive receive autologous stem cell transplantation ( ACST ) per institutional standard part standard care PreASCT participant may consent eligible begin treatment ASCT , must fulfill inclusion exclusion criterion PostASCT participant must initiate day 1 protocol therapy within 3060 day post stem cell reinfusion ; consult study PI exception time frame Recovery ASCT toxicity define outpatient status , able drink , eat normally , need intravenous hydration prior day 1 therapy Achieved least stable disease salvage treatment determine positron emission tomography ( PET ) /computed tomography ( CT ) use 2014 Lugano Classification prior ASCT Brentuximab vedotin naive OR least stable disease Lugano Classification prior brentuximab vedotin treatment Absolute neutrophil count ( ANC ) &gt; = 1000/mm^3 Platelets &gt; = 50,000/mm^3 Hemoglobin &gt; = 8 g/dL Total bilirubin = &lt; 1.5 x upper limit normal ( ULN ) 3 x ULN Gilbert 's disease Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) = &lt; 2.5 x ULN Creatinine clearance &gt; = 40 mL/min per 24 hour urine collection CockcroftGault formula Forced expiratory volume one second ( FEV1 ) carbon monoxide diffusion capacity ( DLCO ) ( adjust Hb ) &gt; = 50 % adjusted Women childbearing potential ( WOCBP ) : Negative urine serum pregnancy test ( minimum sensitivity 25 IU/L equivalent unit human chorionic gonadotropin [ HCG ] ) If urine test positive confirm negative , serum pregnancy test require Woman childbearing potential ( WOCBP ) : use two effective method contraception ( hormonal barrier method ) surgically sterile , abstain heterosexual activity course study 7 month post last dose nivolumab WOCBP define surgically sterilize free menses &gt; 1 year Male : use two effective method contraception ( barrier method ) abstain heterosexual activity first dose study therapy 7 month post last dose nivolumab PostASCT antilymphoma investigational therapy ; immediate postASCT consolidative radiation therapy allow long occurs prior initiation study therapy ; baseline image pulmonary function test ( PFTs ) must perform completion radiation Previous allogeneic transplant Total carmustine ( BCNU ) dose &gt; 600 mg/m^2 prior treatment include transplant condition regimen Live vaccine within 30 day prior day 1 protocol therapy ( e.g . measles , mumps , rubella , varicella , yellow fever , rabies , Bacillus CalmetteGuerin [ BCG ] , oral polio vaccine , oral typhoid ) Refractory prior brentuximab vedotin ( i.e . progression treatment ) Refractory prior antiPD1/PDL1 agent History prior &gt; = grade 3 hypersensitivity either brentuximab vedotin nivolumab History another primary malignancy remission least 3 year ; exception include : Basal cell carcinoma skin Squamous cell carcinoma skin undergone potentially curative therapy In situ cervical cancer Known active central nervous system ( CNS ) involvement lymphoma , include parenchymal and/or lymphomatous meningitis History progressive multifocal leukoencephalopathy ( PML ) Grade &gt; = 2 peripheral neuropathy present time Prior diagnosis inherit acquired immunodeficiency Condition require systemic treatment either corticosteroid ( &gt; 10 mg daily prednisone equivalent ) immunosuppressive medication within 14 day study drug administration ; exception : Inhaled topical steroid Adrenal replacement dose &gt; 10 mg daily prednisone equivalent absence active autoimmune disease Uncontrolled illness include ongoing active infection History active pneumonitis interstitial lung disease : For history pneumonitis exclusion , patient require supplemental oxygen corticosteroid treatment ; radiographic change alone exclusion An active , know suspected autoimmune disease ; follow exception : Vitiligo Hemolytic anemia associate lymphoma ( history present time ) Type I diabetes mellitus Residual hypothyroidism due autoimmune condition require hormone replacement Psoriasis require systemic treatment , Conditions expect recur absence external trigger Active know history ( standard preASCT assessment ) : Hepatitis B C infection Human immunodeficiency virus ( HIV ) Acquired immunodeficiency syndrome ( AIDS ) Women pregnant lactate History cerebral vascular event ( stroke transient ischemic attack ) , unstable angina , myocardial infarction , cardiac symptom consistent New York Heart Association Class IIIIV within 6 month prior day 1 protocol therapy History current evidence condition , therapy , laboratory abnormality might confound result trial , interfere subject 's participation full duration trial , best interest subject participate , opinion treat investigator Prospective participant , opinion investigator , may able comply study procedure ( include compliance issue relate feasibility/logistics )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>